Immunogenicity of COVID-19 booster vaccination in IEI patients and their one year clinical follow-up after start of the COVID-19 vaccination program

PurposePrevious studies have demonstrated that the majority of patients with an inborn error of immunity (IEI) develop a spike (S)-specific IgG antibody and T-cell response after two doses of the mRNA-1273 COVID-19 vaccine, but little is known about the response to a booster vaccination. We studied...

Full description

Bibliographic Details
Main Authors: Leanne P. M. van Leeuwen, Marloes Grobben, Corine H. GeurtsvanKessel, Pauline M. Ellerbroek, Godelieve J. de Bree, Judith Potjewijd, Abraham Rutgers, Hetty Jolink, Frank L. van de Veerdonk, Marit J. van Gils, Rory D. de Vries, Virgil A. S. H. Dalm, VACOPID Research Group, Eric C.M. van Gorp, Faye de Wilt, Susanne Bogers, Lennert Gommers, Daryl Geers, Marianne W. van der Ent, P. Martin van Hagen, Jelle W. van Haga, Bregtje A. Lemkes, Annelou van der Veen, Rogier W. Sanders, Karlijn van der Straten, Judith A. Burger, Jacqueline van Rijswijk, Khadija Tejjani, Joey H. Bouhuijs, Karina de Leeuw, Annick A.J.M. van de Ven, S.F.J. de Kruijf-Bazen, Pieter van Paassen, Lotte Wieten, Petra H. Verbeek-Menken, Annelies van Wengen, Anke H.W. Bruns, Helen L. Leavis, Stefan Nierkens
Format: Article
Language:English
Published: Frontiers Media S.A. 2024-04-01
Series:Frontiers in Immunology
Subjects:
Online Access:https://www.frontiersin.org/articles/10.3389/fimmu.2024.1390022/full